Black Diamond Therapeutics, Inc.
BDTX
$2.59
-$0.10-3.87%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 70.00M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 70.00M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 70.00M | -- | -- |
| SG&A Expenses | 3.54M | 4.10M | 4.96M | 3.03M | 5.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.98M | 13.42M | 15.47M | 15.33M | 18.13M |
| Operating Income | -10.98M | -13.42M | 54.53M | -15.33M | -18.13M |
| Income Before Tax | -8.50M | -10.56M | 56.54M | -15.99M | -15.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.50M | -10.56M | 56.54M | -15.99M | -15.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.50M | -10.56M | 56.54M | -15.99M | -15.56M |
| EBIT | -10.98M | -13.42M | 54.53M | -15.33M | -18.13M |
| EBITDA | -10.89M | -13.33M | 54.62M | -15.25M | -18.04M |
| EPS Basic | -0.15 | -0.19 | 1.00 | -0.28 | -0.28 |
| Normalized Basic EPS | -0.09 | -0.12 | 0.62 | -0.15 | -0.17 |
| EPS Diluted | -0.15 | -0.19 | 0.98 | -0.28 | -0.28 |
| Normalized Diluted EPS | -0.09 | -0.12 | 0.61 | -0.15 | -0.17 |
| Average Basic Shares Outstanding | 56.93M | 56.80M | 56.66M | 56.61M | 56.51M |
| Average Diluted Shares Outstanding | 56.93M | 56.80M | 57.67M | 56.61M | 56.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |